Serum MicroRNAs as New Diagnostic Biomarkers for Pre– and Post–Kidney Transplantation

Sui, Weiguo; Yang, Ming; Li, F.; Chen, H.; Chen, J.; Ou, Minglin; Zhang, Y.; Hua, Lin; Xue, Wen; Dai, Yong

doi:10.1016/j.transproceed.2014.08.050

Cited by 17 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3C). It has previously been reported in the serum of patients with nephrotic syndrome that miR-181a might represent a potential biomarker (Sui et al 2014a) and also might be used as an early diagnostic marker in kidney transplantation (Sui et al 2014b). Based on these recent studies it is important to note, however, that expression of miR-181a was found up-regulated in the serum of patients with nephrotic syndrome and end-stage renal kidney disease, whereas in our analyses from all stages of CKD patients, the exosomal abundance of miR-181a was found to be significantly decreased (Supplemental Fig.…”

Section: Differential Abundance Of Exosomal Mirnas In Ckd Patients Vementioning

confidence: 99%

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Khurana

Ranches

Schafferer

et al. 2016

RNA

116

117

View full text Add to dashboard Cite

In chronic kidney disease (CKD), the decline in the glomerular filtration rate is associated with increased morbidity and mortality and thus poses a major challenge for healthcare systems. While the contribution of tissue-derived miRNAs and mRNAs to CKD progression has been extensively studied, little is known about the role of urinary exosomes and their association with CKD. Exosomes are small, membrane-derived endocytic vesicles that contribute to cell-to-cell communication and are present in various body fluids, such as blood or urine. Next-generation sequencing approaches have revealed that exosomes are enriched in noncoding RNAs and thus exhibit great potential for sensitive nucleic acid biomarkers in various human diseases. Therefore, in this study we aimed to identify urinary exosomal ncRNAs as novel biomarkers for diagnosis of CKD. Since up to now most approaches have focused on the class of miRNAs, we extended our analysis to several other noncoding RNA classes, such as tRNAs, tRNA fragments (tRFs), mitochondrial tRNAs, or lincRNAs. For their computational identification from RNA-seq data, we developed a novel computational pipeline, designated as ncRNASeqScan. By these analyses, in CKD patients we identified 30 differentially expressed ncRNAs, derived from urinary exosomes, as suitable biomarkers for early diagnosis. Thereby, miRNA-181a appeared as the most robust and stable potential biomarker, being significantly decreased by about 200-fold in exosomes of CKD patients compared to healthy controls. Using a cell culture system for CKD indicated that urinary exosomes might indeed originate from renal proximal tubular epithelial cells.

show abstract

Section: Differential Abundance Of Exosomal Mirnas In Ckd Patients Vementioning

confidence: 99%

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Khurana

Ranches

Schafferer

et al. 2016

RNA

116

117

View full text Add to dashboard Cite

show abstract

“…Further supporting this concept, serum miRNAs have been proposed as potential prognostic biomarkers in different transplantation settings [4,15,16]. Due to cohort constrains we were not able to assess potential correlations between the miRNAs investigated in this study and other biomarkers, including inflammatory cytokines.…”

Section: Discussionmentioning

confidence: 80%

Serum miRNAs as Potential Biomarkers for the Bronchiolitis Obliterans Syndrome after Lung Transplantation

Budding

Rossato

Graaf

et al. 2016

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

A B S T R A C TLung transplantation (LTx) is the last treatment for patients suffering from end-stage lung diseases. Survival postLTx is hampered by the development of the bronchiolitis obliterans syndrome (BOS) and diagnosis is often late. Given the urgent clinical need to recognize BOS patients at an early stage, we analyzed circulating miRNAs to identify possible stratification markers for BOS development post-transplantation. Therefore, pro-fibrotic (miR-21, miR-155), anti-fibrotic (miR-29a) and fibrosis-unrelated (miR-103, miR-191) miRNAs were analyzed in serum of end-stage lung disease patients and during LTx follow-up.Significant elevated levels of serum miRNAs were observed for all investigated miRNAs in both chronic obstructive pulmonary disease and interstitial lung disease patients compared to healthy controls. The same miRNAs were also significantly increased in the serum of BOS + vs. BOS− patients. Most importantly, miR-21, miR-29a, miR-103, and miR-191 levels were significantly higher in BOS+ patients prior to clinical BOS diagnosis.We demonstrated that a selected group of miRNAs investigated is elevated in end-stage lung disease and BOS + patients, prior to clinical BOS diagnosis. Even if further research is expedient on the prognostic value of circulating miRNAs in BOS and lung conditions in general, these results strongly suggest that circulating miRNAs could be used as potential biomarkers for BOS development.

show abstract

“…The same is reported for diabetic nephropathy [27], systemic vasculitis [28] and lupus nephritis [29]. Circulating miRNA-21 might serve as a biomarker for kidney fibrosis [30] and Sui et al [31] and Bijkerk et al [32] reported the use of miRNAs in renal transplantation. Finally, Lorenzen [33] summarized the miRNA expression profile changes in renal ischaemia-reperfusion injury.…”

mentioning

confidence: 67%

Circulating miRNAs as biomarkers of kidney disease

Hüttenhofer

Mayer

2016

Clin Kidney J

View full text Add to dashboard Cite

Interest in microRNAs (miRNAs) has dramatically increased in recent years not only because they regulate mRNA expression, and thus many physiological or pathophysiological processes, but also because they could serve as biomarkers. Next to analysis of tissue miRNA expression, measurement in body fluids such as blood or urine is attractive because miRNA in microvesicles or bound to protein is very stable. Currently it is unclear whether these circulating miRNAs are tissue and disease specific or represent more general pathologies like inflammation. In addition pre-analytical sample handling and variable analysis techniques affect the results and thus much more work needs to be done before one can draw a final conclusion about their clinical utility.

show abstract

Serum MicroRNAs as New Diagnostic Biomarkers for Pre– and Post–Kidney Transplantation

Cited by 17 publications

References 21 publications

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease

Serum miRNAs as Potential Biomarkers for the Bronchiolitis Obliterans Syndrome after Lung Transplantation

Circulating miRNAs as biomarkers of kidney disease

Contact Info

Product

Resources

About